Anti-Human IL-3R alpha & CD3 epsilon Bispecific Reference Antibody (Mipletamig, RUO) (HB714126)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HB714126

Description

Mipletamig (HB714126) is a research-grade recombinant antibody targeting CD123. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Species reactivity

Human

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo, WB

Host species

Humanized

Isotype

Immunoglobulin IG chain scFvkh-G1hCH2CH3-scFvhk dimer bisdisulfide

Expression system

Mammalian Cells

Clonality

Monoclonal

Tested applications

Target

IL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain

Endotoxin level

Please contact the lab for this information.

Purity

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P26951 & P07766

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternate Names

Bispecific, Tetravalent, 2839556-21-5

Background

Vibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Mipletamig.
Western blot

Western blot analysis was performed using anti-IL3RA monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human IL3RA (Catalog No: HB714021)
Lane 2: recombinant human CD3E (Catalog No: HY057021)